The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

Living with IPF is never dull, says columnist Sam Kirton, who shares some updates on topics he's discussed in recent columns.

The winner of the Established Business to Business category in The Australian Financial Review Customer Champions list 2024, ...

Panagiotis Tarinidis has unofficially exceeded the U66KG IPF Raw Total World Record with a score of 713 kilograms (1,571.9 ...

A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...

Idiopathic pulmonary fibrosis (IPF) is a fatal disease that's all the more difficult for patients because of a lack of awareness and investment in supporting people with the condition. In the week ...

While Michigan State University’s Infrastructure, Planning and Facilities are trying to take more aggressive measures to stop ...

IPF severely impacts quality of life, limiting daily activities due to progressive respiratory decline. Median survival for IPF patients is approximately 3 to 5 years post-diagnosis. The financial ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...

Columnist Sam Kirton is doing a service for him and his family's future generations by sharing his research on the family ...

The Association of Real Estate Funds (AREF), the British Property Federation (BPF) and the Investment Property Forum (IPF) ...

Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation. Comprehensive evaluation is crucial to tailor treatment plans ...